Immunotherapeutic approaches for the treatment of breast cancer

被引:15
作者
Knutson, KL [1 ]
Schiffman, K [1 ]
Rinn, K [1 ]
Disis, ML [1 ]
机构
[1] Univ Washington, Div Oncol, Seattle, WA 98195 USA
关键词
breast cancer; immunotherapy; T cell; vaccines; cytokines; adoptive T cell therapy;
D O I
10.1023/A:1018714300217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The application of immunotherapeutic principles to the treatment and prevention of breast cancer is a relatively new undertaking. Although cytokine infusions, cancer vaccines, and T cell therapy have been extensively studied in solid tumors such as melanoma and renal cell carcinoma, the therapeutic efficacy of these approaches is not well explored in breast cancer. The recent definition of tumor-specific immunity in breast cancer patients and the identification of several breast cancer antigens has generated enthusiasm for the application of immune-based therapies to the treatment of breast malignancies. In general, immunotherapies can be considered either non-specific, such as a general immunomodulator (e.g., a cytokine), or tumor-specific (e.g., a vaccine that targets breast cancer tumor antigens). This review describes three major immunotherapeutic strategies that have the potential to enhance or generate an anti-breast cancer T cell immune response: (i) cytokine therapy: (ii) cancer vaccines; and (iii)T cell therapy, and explores how each strategy has been applied to the treatment of breast cancer.
引用
收藏
页码:353 / 365
页数:13
相关论文
共 85 条
[1]   INTRATUMORAL INJECTION OF AN ADENOVIRUS EXPRESSING INTERLEUKIN-2 INDUCES REGRESSION AND IMMUNITY IN A MURINE BREAST-CANCER MODEL [J].
ADDISON, CL ;
BRACIAK, T ;
RALSTON, R ;
MULLER, WJ ;
GAULDIE, J ;
GRAHAM, FL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8522-8526
[2]   LYSIS OF AUTOLOGOUS MELANOMA-CELLS BY TUMOR-INFILTRATING LYMPHOCYTES - ASSOCIATION WITH CLINICAL-RESPONSE [J].
AEBERSOLD, P ;
HYATT, C ;
JOHNSON, S ;
HINES, K ;
KORCAK, L ;
SANDERS, M ;
LOTZE, M ;
TOPALIAN, S ;
YANG, J ;
ROSENBERG, SA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) :932-937
[4]   Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer [J].
Ahlert, T ;
Sauerbrei, W ;
Bastert, G ;
Ruhland, S ;
Bartik, B ;
Simiantonaki, N ;
Schumacher, J ;
Hacker, B ;
Schumacher, M ;
Schirrmacher, V .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1354-1366
[5]   Changes in cytokine production of breast cancer patients treated with interferons [J].
Barak, V ;
Kalickman, I ;
Nisman, B ;
Farbstein, H ;
Fridlender, ZG ;
Baider, L ;
Kaplan, A ;
Stephanos, S ;
Peretz, T .
CYTOKINE, 1998, 10 (12) :977-983
[6]   THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].
BARON, S ;
TYRING, SK ;
FLEISCHMANN, WR ;
COPPENHAVER, DH ;
NIESEL, DW ;
KLIMPEL, GR ;
STANTON, GJ ;
HUGHES, TK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383
[7]   Making the most of mucin: A novel target for tumor immunotherapy [J].
BarrattBoyes, SM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (03) :142-151
[8]  
BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO
[9]  
2-1
[10]   Hematologic effects of flt3 ligand in vivo in mice [J].
Brasel, K ;
McKenna, HJ ;
Morrissey, PJ ;
Charrier, K ;
Morris, AE ;
Lee, CC ;
Williams, DE ;
Lyman, SD .
BLOOD, 1996, 88 (06) :2004-2012